Literature DB >> 7492757

Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice.

X Q Yan1, D Lacey, F Fletcher, C Hartley, P McElroy, Y Sun, M Xia, S Mu, C Saris, D Hill, R G Hawley, I K McNiece.   

Abstract

Megakaryocyte growth and development factor (MGDF) has recently been identified as a ligand for the c-mpl receptor. Using retroviral-mediated gene transfer, MGDF has been overexpressed in mice to evaluate the systematic effects due to chronic exposure to this growth factor. MGDF overexpressing mice had more rapid platelet recovery than control mice after transplantation. Following this recovery, the platelet levels continued increasing to fourfold to eightfold above normal baseline levels and remained elevated (five-fold above control mice) in these animals, which are alive and well at more than 4 months posttransplantation. Increased megakaryocyte numbers were detected in a number of organs in these mice including bone marrow, spleen, liver, and lymph nodes. Prolonged overexpression of MGDF led to decreased marrow hematopoiesis, especially erythropoiesis, with a shift to extramedullary hematopoiesis in the spleen and liver. All the MGDF overexpressing mice analyzed to date developed myelofibrosis and osteosclerosis, possibly induced by megakaryocyte and platelet produced cytokines. No significant effect on other hematopoietic lineages was seen in the MGDF overexpressing mice, showing that the stimulatory effect of MGDF in vivo is restricted to the megakaryocyte lineage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492757

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 2.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

3.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

Review 4.  Toxicities of the thrombopoietic growth factors.

Authors:  Adam Cuker
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

5.  Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Authors:  David J Olivos; Marta Alvarez; Ying-Hua Cheng; Richard Adam Hooker; Wendy A Ciovacco; Monique Bethel; Haley McGough; Christopher Yim; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

6.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11.

Authors:  R G Hawley; T S Hawley; A Z Fong; C Quinto; M Collins; J P Leonard; S J Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation.

Authors:  Wendy A Ciovacco; Ying-Hua Cheng; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

8.  Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation.

Authors:  Justin M Lemieux; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-04-01       Impact factor: 4.429

Review 9.  New thrombopoietic growth factors.

Authors:  David J Kuter
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

10.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.